跳至主要内容
临床试验/NCT07162337
NCT07162337招募中不适用

BILMOD: BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年6月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
1
主要终点
Change in Stool Metabolomics

研究概览

简要总结

This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer.

详细描述

In this research study, the investigators are:

  • Investigating the effect of more plant-based and less animal-based food intake on bile acid metabolomic composition in stool among individuals with a history of colorectal adenoma.
  • Investigating the effect of more plant-based and less animal-based food intake on plasma bile acid metabolomic composition, the gut microbiome, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer among individuals with a history of colorectal adenoma.

Based on the following evidence:

  • Growing evidence indicates that the gut microbiome and its metabolites play important roles in mediating the dietary effects on colorectal cancer risk
  • Secondary bile acids are increasingly appreciated as important metabolites underlying the metabolic link between Western diet, the gut microbiome, and colorectal cancer
  • Evidence suggests that secondary bile acids trigger a plethora of tumorigenic effects in the colon, including inflammation, oxidative DNA damage, and apoptosis resistance
  • Epidemiological studies have revealed that a higher circulating level of secondary bile acids, particularly deoxycholic acid and lithocholic acid, was associated with an increased risk of colorectal cancer
  • High fat intake has been repeatedly reported to increase secondary bile acids, but the findings on how other nutrients or foods in Western diet may influence secondary bile acids remain mixed

The research procedures include screening for eligibility, study intervention, and scheduling two clinical research visits:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Underwent screening or surveillance colonoscopy with removal of at least one adenoma.
  • •Age 18-80 years.
  • •Habitually consume a Western pattern diet.
  • •BMI of at least 18.5 kg/m2 but less than 35 kg/m2
  • •Weight stable in last 3 months (loss or gain <4%).
  • •Subjects must be able and willing to follow study procedures and instructions.
  • •Ability to understand and the willingness to sign a written informed consent document.

排除标准

  • •Strict dietary patterns (e.g., vegan, carnivore, kosher, low-carb etc.).
  • •Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis.
  • •Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of nonmelanoma skin) in which there has been any active treatment within the last three years.
  • •Known diagnosis of Familial Adenomatous Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC, Lynch Syndrome).
  • •Any adenoma that was not completely removed during previous colonoscopy.
  • •Known bleeding tendency/condition (e.g. von Willebrand disease) or history of peptic ulcer or gastrointestinal bleed requiring hospitalization, endoscopic complications, or contraindication to colonoscopy.
  • •Current use of anticoagulant therapies, including Heparin, Warfarin, Dalteparin sodium, Bivalirudin, Argatroban, Lepirudin, Heparin Sodium, Heparin/Dextrose, and an unwillingness or inability to discontinue anticoagulants.
  • •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • •Regular use of aspirin.
  • •Use of antibiotics or probiotics.
  • •Inability or unwillingness to abstain from limited consumption of animal-based food or to provide blood or stool samples during the study.
  • •Participants who are receiving any other investigational agents.
  • •Pregnant or breastfeeding.
  • •Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.

研究组 & 干预措施

Increased Plant-Based Diet and Decreased Animal-Based Diet

Experimental

Participants will be instructed to self-regulate their diet by increasing the amount of plant-based foods while decreasing the amount of animal-based foods for a 4-week period.

干预措施: Increased Plant-Based Diet and Decreased Animal-Based Diet (Behavioral)

结局指标

主要结局

Change in Stool Metabolomics

时间窗: From Baseline to Final Visit (5 weeks)

Comparing change in stool metabolomics, using non-targeted global metabolomics analysis on stool samples to examine intensity changes in the stool metabolite profile.

次要结局

  • Relative Composition of Gut Microbiome(From Baseline to Final Visit (5 weeks))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew T. Chan, MD, MPH

Principal Investigator

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验